Rajeev Dadoo - 25 Jun 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Reporting relationship: Director
Issuer ticker: SPRY
Reported as of: 25 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jun 2025, 16:43:08 UTC
Prior SEC filing: 24 Jun 2024
Next SEC filing: 26 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Sasha Keough, attorney-in-fact for Rajeev Dadoo

Key filing fact

Rajeev Dadoo filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 27 Jun 2025.

Key facts

This page summarizes Rajeev Dadoo's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Jun 2025, 16:43.

Change

Previous filing in this sequence was filed on 24 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001951685 Primary reporting owner

Dadoo Rajeev

Relationship: Director
Address: 985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE
Signature: /s/ Sasha Keough, attorney-in-fact for Rajeev Dadoo
Signature date: 27 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRY transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 25 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $17.26
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.